who's head did Joe use? And did he give the border guards the heads up? I can't imagine where this is all heading.
Furthermore if the ASH data confirms that 40% went into remission and 100% (9 of 9) into remission in the MDS RARS not only will Imetelstat validate it's first in class oncology drug title but a multi use cancer treatment indication application.
Can't you easily see a 400% gain in SP on the upside?
Geron is getting the Mayo IND at the end of September, however and even more important, they already have all the DATA from Mayo, and that is VERY significant. They are using that data "to inform the the new Phase 2 trial" which means they are certainly moving forward and the data from MC will help inform them on dosages, mylosuppressive effects etc. This is very good news.
The 33 patients still enrolled in the Mayo all have CI or PR or CR. That is remarkable and not fully appreciated. We don't know exactly the status of the MDS patients, but we do know that every single one is still enrolled more than 8 months later. Can Jakafi claim anything close to this?
...if you read the entire thread you'd know the number 33 CR came from
CDKN1A/Imetelstat's July Yale abstract, not Maine's cheese impacted conjectured colon.
implied, lumped or deliberately omitted for a "ASH" worthy abstract to be presented at a later date who knows until it is presented. It certainly would be a hot tamale for INCY to handle.
No problem Biopearl, always appreciate your contributions to the board's discussion.
Dr. David Snyder, City of Hope, Duarte, California Transplants and Imetelstat https://www.youtube.com/watch?v=wlymlEjeGks
Synergistic tumor suppression by combined inhibition of telomerase using imetelstat and other oncology drugs is but one of a growing list of other possible indications. Another abstract to add to the growing list for worthwhile discussion come ASH.
Imetelstat: First-in-class Telomerase Inhibitor
• First telomerase inhibitor in clinical development
• 13-mer modified oligonucleotide with palmitoyl lipid
tail (not to be confused with a beaver tail)
• Competitively binds to RNA template of telomerase
• Potent inhibitor of telomerase enzyme activity
– IC50 = 0.5-10 nM (cell-free)
– IC50 = 0.15-1.77 µM (cell-based)
• Long half-life in bone marrow, spleen and liver
– Tissue t½ = 50-90 hr in rodents
– Predicted human t½ = 41 hr with doses 7.5-11.7 mg/kg
...was referring to Syder's June presentation RE: ET CR & PR response: "all patients achieved std CR, 30 month follow up showing maintenance of response lasting 1-2 years" That's what I heard from him.
...in my neck of the woods dammn is spelled dam.
The registration date deadline was Aug 3. Abstracts accepted for presentation at the meeting will be published on November 6, 2014. Hard to tell who's on the roster yet. E2W said he hadn't seen Tefferi registered.
Dr. Syder's earlier presentation on Imetelstat had covered endpoints in relation to Imetelstat and it's disease modifying attributes wrt MF. This certainly puts more clarity in new phase II trial designs going fwd., a seemingly stumbling block for Scarlett at earlier CC's
Imetelstat's trials in Myelofibrosis had shown positive results in Essential Thrombocythemia, Polycythemia Vera, Myelodysplastic Syndrome, Acute Myeloid Leukemia (blast phase). Info updates concerning these trial application I would think would all be worthy of discussion at ASH.
if we hit $5 you'll be able to fly business class on Delta or Virgin, but I hear you on the smaller airport preference.
BF, you obviously didn't follow the SP and vol movement in June prior to the partial lift on the MC's MF 1ST NDA. Same start as yesterday. We had a 50% SP increase within 3 days. This time it could be much more.
``8.Other papers on Imetelstat expected at ASH``
this should read.... AML & MLS data yet to be presented by Tefferi outside of ASH.
we hit 3.4mil shares with a 10 cent pop, SP dropped back down this afternoon on lower vol. and an ugly market. All points to a positive change in sentiment on GERN.